PMID- 37792223
OWN - NLM
STAT- MEDLINE
DCOM- 20240415
LR  - 20240417
IS  - 1573-7233 (Electronic)
IS  - 0167-7659 (Linking)
VI  - 43
IP  - 1
DP  - 2024 Mar
TI  - Modulation of hypoxia-inducible factor-1 signaling pathways in cancer 
      angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and 
      critical review.
PG  - 501-574
LID - 10.1007/s10555-023-10136-9 [doi]
AB  - Tumor cells employ multiple signaling mediators to escape the hypoxic condition 
      and trigger angiogenesis and metastasis. As a critical orchestrate of tumorigenic 
      conditions, hypoxia-inducible factor-1 (HIF-1) is responsible for stimulating 
      several target genes and dysregulated pathways in tumor invasion and migration. 
      Therefore, targeting HIF-1 pathway and cross-talked mediators seems to be a novel 
      strategy in cancer prevention and treatment. In recent decades, tremendous 
      efforts have been made to develop multi-targeted therapies to modulate several 
      dysregulated pathways in cancer angiogenesis, invasion, and metastasis. In this 
      line, natural compounds have shown a bright future in combating angiogenic and 
      metastatic conditions. Among the natural secondary metabolites, we have evaluated 
      the critical potential of phenolic compounds, terpenes/terpenoids, alkaloids, 
      sulfur compounds, marine- and microbe-derived agents in the attenuation of HIF-1, 
      and interconnected pathways in fighting tumor-associated angiogenesis and 
      invasion. This is the first comprehensive review on natural constituents as 
      potential regulators of HIF-1 and interconnected pathways against cancer 
      angiogenesis and metastasis. This review aims to reshape the previous strategies 
      in cancer prevention and treatment.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Fakhri, Sajad
AU  - Fakhri S
AUID- ORCID: 0000-0001-8265-8284
AD  - Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University 
      of Medical Sciences, Kermanshah, 6734667149, Iran.
FAU - Moradi, Seyed Zachariah
AU  - Moradi SZ
AUID- ORCID: 0000-0003-0579-3495
AD  - Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University 
      of Medical Sciences, Kermanshah, 6734667149, Iran.
AD  - Medical Biology Research Center, Health Technology Institute, Kermanshah 
      University of Medical Sciences, Kermanshah, 6734667149, Iran.
FAU - Faraji, Farahnaz
AU  - Faraji F
AUID- ORCID: 0000-0002-5476-3463
AD  - Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
FAU - Kooshki, Leila
AU  - Kooshki L
AUID- ORCID: 0000-0003-1071-1917
AD  - Student Research Committee, Kermanshah University of Medical Sciences, 
      Kermanshah, 6714415153, Iran.
FAU - Webber, Kassidy
AU  - Webber K
AUID- ORCID: 0000-0002-9777-9342
AD  - College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, 5000 
      Lakewood Ranch Boulevard, Bradenton, FL, 34211, USA.
FAU - Bishayee, Anupam
AU  - Bishayee A
AUID- ORCID: 0000-0001-9159-960X
AD  - College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, 5000 
      Lakewood Ranch Boulevard, Bradenton, FL, 34211, USA. abishayee@lecom.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231004
PL  - Netherlands
TA  - Cancer Metastasis Rev
JT  - Cancer metastasis reviews
JID - 8605731
RN  - 0 (Hypoxia-Inducible Factor 1)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
SB  - IM
MH  - Humans
MH  - Cell Line, Tumor
MH  - Hypoxia
MH  - *Hypoxia-Inducible Factor 1
MH  - Hypoxia-Inducible Factor 1, alpha Subunit
MH  - *Neoplasms/drug therapy/pathology
MH  - Neovascularization, Pathologic
MH  - Signal Transduction
OTO - NOTNLM
OT  - Angiogenesis
OT  - Cancer
OT  - Hypoxia-inducible factor-1
OT  - Metastasis
OT  - Natural agents
OT  - Therapeutic targets
EDAT- 2023/10/04 12:43
MHDA- 2024/04/15 06:42
CRDT- 2023/10/04 11:12
PHST- 2023/08/17 00:00 [received]
PHST- 2023/09/07 00:00 [accepted]
PHST- 2024/04/15 06:42 [medline]
PHST- 2023/10/04 12:43 [pubmed]
PHST- 2023/10/04 11:12 [entrez]
AID - 10.1007/s10555-023-10136-9 [pii]
AID - 10.1007/s10555-023-10136-9 [doi]
PST - ppublish
SO  - Cancer Metastasis Rev. 2024 Mar;43(1):501-574. doi: 10.1007/s10555-023-10136-9. 
      Epub 2023 Oct 4.